Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective BPDCN chemotherapy historical control study for ELZONRIS registry
NL-OMON58436Not yet recruiting
- Sponsor
- Stemline Therapeutics
- Start
- Aug 2025
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of tagraxofusp in Blastic plasmacytoid dendritic cell neoplasm (BPDCN) (2 arms), sponsored by Stemline Therapeutics. Primary endpoints: Objective response rate, Composite complete response rate and 8 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
tagraxofusp
03
Conditions
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NL-OMON58436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58436.